The FDA has finalized its regulations on the content and format of labeling for prescription drug products, including biological products. The final labeling regulations, commonly known as the Physician Labeling Rule (PLR), help ensure that health care providers have clear and concise information in prescription drug labeling, and also make it easier for them to assess if the product is appropriate for use by their patient. If you’re developing draft labeling for biosimilar products for submission in a regulatory application, you need to know about the regulations so that you don’t run into any problems later.
Get up to speed with industry veteran Kelly Thomas on the latest FDA guidance for labeling biosimilar products. Learn the Code of Federal Regulations (CFR) for patient labeling, and for revising biosimilar product labeling. Understand the labeling specifics relating to all three sections: i.e. highlights of prescribing information, table of contents, and full prescribing information. And learn how to use the FDA’s final guidance to correctly label biosimilar products, and develop draft labeling for biosimilar products to be submitted in a regulatory application.
Here’s a taste of what you will uncover:
Topic 1: CFR Review
Topic 2: Biosimilar labeling specifics
Topic 3: 2018 FDA Final Guidance for Labeling Biosimilar Products
Who Should Attend
Ask a question at the Q&A session following the live event and get advice unique to your situation, directly from our expert speaker.
- Casper E. Uldriks
Kelly Thomas has over two decades of cGMP hands-on industry experience in both pharmaceutical and medical device manufacturing operations. Her experience covers all Quality Systems; as well as, all areas of validation; including, process/product validation, facilities validation, CSV and 21 CFR Part 11, test method validation, equipment/automated processes and cleaning validation.